Empagliflozin Enhances Hepatic Glucose Production and Reduces Total-Body Norepinephrine Turnover Rate: A Randomized Trial
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) cause an increase in hepatic glucose production (HGP). We previously showed that SGLT2i cause a rapid (within 4 h) increase in the total-body norepinephrine (NE) turnover rate, which could explain the increase in HGP. Because the increase in HGP caused by SGLT2i is long-lasting, we examined the long-term effect of SGLT2i on the NE turnover rate. Empagliflozin caused a decrease in total-body NE turnover at 1 day and at 12 weeks after starting therapy, despite an increase in glucose production, and the magnitude of decrease in NE turnover inversely correlated with the increase in HGP caused by empagliflozin.
Authors
- Muhammad Abdul‐Ghani (ORCID: https://orcid.org/0000-0003-4556-1787)
- Renata Belfort De Aguiar
- Aurora Merovci
- Jehad Abubaker (ORCID: https://orcid.org/0000-0003-0681-7305)
- Fahd Al‐Mulla (ORCID: https://orcid.org/0000-0001-5409-3829)
- Siham Abdelgani
- Gozde Baskoy
- Ralph A. DeFronzo (ORCID: https://orcid.org/0000-0002-8581-6273)
- Mohamed Abu‐Farha (ORCID: https://orcid.org/0000-0001-8357-1252)
- John M. Adams (ORCID: https://orcid.org/0000-0002-6794-6904)
- Ahmed A. Khattab
Institutions
- The University of Texas at San Antonio Health Science Center (US)
- Texas Diabetes Institute (US)
- Dasman Diabetes Institute (KW)
Publication Details
- Journal
- Diabetes
- Published
- 2025-07-16
- DOI
- https://doi.org/10.2337/db25-0210
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Intarcia Therapeutics
- Novo Nordisk
- National Institutes of Health
- National Institute of Diabetes and Digestive and Kidney Diseases